Exit readiness for a DME supplier means transforming billing accuracy, payer mix, inventory controls, and A/R hygiene into verifiable evidence that can withstand institutional diligence. We build these systems over 12 to 18 months, not in the final quarter before marketing.
No cost. 15 minutes. No obligation.
Exit readiness for a DME supplier means transforming billing accuracy, payer mix, inventory controls, and A/R hygiene into verifiable evidence that can withstand institutional diligence. We build these systems over 12 to 18 months, not in the final quarter before marketing.
DME suppliers pursuing exit often discover that their billing error rates, aging receivables, and payer concentration cannot survive the scrutiny of a sophisticated buyer. Strategic acquirers and private equity groups model collection velocity, denial rates, and inventory turns line by line, and they discount offers aggressively when reimbursement documentation is incomplete or owner relationships with Medicare intermediaries are undocumented. Many operators believe a trailing twelve months of revenue is sufficient evidence, but buyers demand proof that EBITDA is repeatable under institutional ownership without the founder managing denials or smoothing payer appeals manually. Exit readiness is the process of converting operational habits into auditable systems that produce predictable cash collection independent of the current owner.
Billing accuracy audit and denial rate improvement plan with specific corrective actions tied to clean claim percentage and first-pass resolution rate
A/R aging scrub and reserve methodology that aligns your book value of receivables with collectible value under buyer quality of earnings assumptions
Payer mix rebalancing roadmap to reduce concentration risk and document transferability of Medicare and commercial contracts independent of owner relationships
Inventory turnover analysis by product category with obsolescence reserves and reorder disciplines that buyers can verify through perpetual system reconciliation
Collections process documentation including appeal workflows, payer portals, and claim edit rules that transfer to institutional management without margin degradation
Pre-diligence financial package with normalized EBITDA, add-back support, and KPI trending that matches the format private equity groups and strategic buyers expect in healthcare services
Proof of delivery and compliance file structure that passes mock CERT audit and demonstrates sustainable reimbursement under post-close ownership
DME buyers pay 3 to 6x EBITDA for commodity equipment operations, but respiratory and CPAP platforms with clean billing command 7 to 12x because reimbursement is more predictable and denial rates are structurally lower. The multiple you receive depends entirely on whether your payer mix, inventory controls, and collections process can operate independently under institutional ownership. Buyers model every basis point of denial rate and every day in A/R because those variables directly determine cash conversion and return on invested capital in a reimbursement-driven business.
See the healthcare multiples benchmark for where durable medical equipment suppliers transact today.
Buyers do not pay a multiple on the EBITDA you report. They pay it on the EBITDA they accept after add-backs.
Where healthcare practices transact today, by vertical, on normalized EBITDA.
| Vertical | EBITDA multiple | Basis | Source |
|---|---|---|---|
| DME Suppliers | 3 to 12x | EBITDA by subsegment (small shops on SDE) | CT Acquisitions |
exit readiness and m&a for durable medical equipment suppliers is the intersection page. Read the full durable medical equipment suppliers advisory angle, the general exit readiness and m&a overview, or run the Value Creation Assessment to see where your practice stands.
Twelve to eighteen months is the realistic horizon to clean billing systems, reduce denial rates below 5 percent, scrub aging A/R, and document transferable payer relationships. Operators who begin this work 90 days before going to market typically face material purchase price reductions or failed quality of earnings reviews when buyers discover undocumented add-backs or inflated receivables values.
Billing accuracy and denial rates come first because they determine whether reported EBITDA is repeatable under new ownership. Buyers then model A/R aging to estimate true collectible value, audit inventory for obsolescence, and test whether payer contracts and appeals processes transfer without the owner. Any manual workaround or owner-dependent relationship becomes a price reduction or earnout condition.
Respiratory and CPAP lines command higher multiples, 7 to 12x versus 3 to 6x for commodity DME, because reimbursement is more stable and compliance risk is better understood by institutional buyers. But the shift requires credentialing, supplier agreements, and billing infrastructure that take months to establish. We help you model whether the margin and multiple uplift justify the investment and timeline before you commit capital.
Buyers will age your receivables independently during quality of earnings review and apply collection assumptions much more conservative than yours. A/R over 90 days is typically excluded from working capital or heavily reserved, and any overstatement of collectible receivables reduces your net proceeds dollar for dollar at close. We scrub A/R early and align your reserves with buyer expectations so there are no surprises in final purchase price reconciliation.
We build 13-week rolling cash forecasts that account for Medicare reimbursement lag, inventory replenishment cycles…
See the durable medical equipment suppliers angleProactive tax strategy for DME suppliers means aligning entity structure, owner compensation, and retirement vehicles…
See the durable medical equipment suppliers angleDME suppliers often overpay taxes by treating all owner earnings as W-2 salary, missing the after-tax advantage of…
See the durable medical equipment suppliers angleDME suppliers often reinvest in inventory or draw cash without a unified plan linking reimbursement volatility, payer…
See the durable medical equipment suppliers angleWe build a capital allocation framework that aligns debt, inventory investment, distribution timing, and working…
See the durable medical equipment suppliers angleDME suppliers pricing without job-level visibility lose margin to payer mix variation, billing denials, and delivery…
See the durable medical equipment suppliers angleFor DME suppliers, financial cleanliness means defensible billing records, documented denial workflows, inventory…
See the durable medical equipment suppliers angleDME suppliers need senior financial leadership to manage payer mix, drive down denial rates, and enforce inventory…
See the durable medical equipment suppliers angleProduction per provider, collection rate, and payer mix. Dental practice value lives in the hygiene schedule a
See advisory angleProfitability by provider, location, and payer. Multi-provider groups live and die by payer mix and provider p
See advisory angleRepeat revenue, provider productivity, and margin per service line. Med spas are valued on whether the model r
See advisory angleThe Keystone Value Creation Assessment™ audits your last 12 to 36 months and gives you a written summary whether you engage us or not. If there is not a clear opportunity to create value, we will tell you directly.